Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.
Vir Biotechnology
Posted inCOVID-19, Infections, New Drugs, Regulatory
Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus
One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.
Posted inClinical Trials, COVID-19, Infections
Ensovibep: Drug for All Variants of Coronavirus Including Omicron
Molecular Partners and Novartis believe in the success of DARPins.
Posted inCOVID-19, Infections, Research
Omicron Variant: Latest Scientific News, Findings, Evidence, and Developments
Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.
Posted inClinical Trials, COVID-19, Infections
Sotrovimab Is Effective Against Omicron Variant of Coronavirus
A monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology successfully counteracts a new strain of SARS-CoV-2.